Tratamiento de meduloblastomas en infantes
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The medulloblastoma is the most frequent tumor in the pediatric population. The treatment involves safe maximal resection, chemotherapy and craniospinal radiation in children older than 3 years old. In children under 3 years, the effects of neuroaxis radiation therapy are prohibitive in terms of the development of neurocognitive disorders, so it is usually omitted in this age group. The omission of radiotherapy is associated with a worse oncological prognosis, higher rates of local and distant recurrence. This has motivated to explore multiple treatments alternatives in this age group. We propose a retrospective study in which we analyze patients aged 0 to 4 years old diagnosed with medulloblastoma treated at our center from 2000 to 2022.
11 cases, 5 children under 3 years old. We obtained an overall survival rate at 1 year of 72.7%, at 3 years of 27.2% and at 5 years of 27.2%. The median survival of patients aged 3 years or younger was 13 months. The median survival of those older than 3 years was 32.5 months. The median survival in patients receiving radiation therapy, regardless of age group was 50.5 months.
The results obtained following the PINDA protocol, has delivered results similar to (like) those published in the Baby Pog protocol, which in the light of the most modern publications delivers survival rates that seem to be insufficient, which challenges to incorporate new treatment strategies more specific to each case.
Key words: Medulloblastoma, craniospinal radiotherapy, chemotherapy, central nervous system tumors, infants.
##plugins.themes.bootstrap3.article.details##
Bibliografía
Huang GH, Xu QF, Cui YH, Li N, Bian XW, Lv SQ. Medulloblastoma stem cells: Promising targets in medulloblastoma therapy. Cancer Sci. 2016;107(5):583-589. DOI: https://doi.org/10.1111/cas.12925
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. DOI: https://doi.org/10.1007/s00401-016-1545-1
Vladoiu MC, El-Hamamy I, Donovan LK, et al. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature. 2019;572(7767):67-73. DOI: https://doi.org/10.1038/s41586-019-1158-7
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 [published correction appears in Neuro Oncol. 2018 Nov 17;:null]. Neuro Oncol. 2018;20(suppl_4):iv1-iv86. DOI: https://doi.org/10.1093/neuonc/noy131
Kaatsch P, Grabow D, Spix C: German Childhood Cancer Registry Annual Report 2016. Mainz, Germany: Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, 2017.
Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial [published correction appears in Lancet Oncol. 2006 Oct;7(10):797]. Lancet Oncol. 2006;7(10):813-820. DOI: https://doi.org/10.1016/S1470-2045(06)70867-1
Johnston, Donna L et al. “Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive.” Journal of neuro-oncology vol. 124,2(2015): 247-53. DOI: https://doi.org/10.1007/s11060-015-1831-0
Veneroni L, Boschetti L, Barretta F, et al. Quality of life in long-term survivors treated for metastatic medulloblastoma with a hyperfractionated accelerated radiotherapy (HART) strategy. Childs Nerv Syst. 2017;33(11):1969-1976. DOI: https://doi.org/10.1007/s00381-017-3548-1
Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer. 2008;50(6):1169-1175.
Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328(24):1725-1731. DOI: https://doi.org/10.1056/NEJM199306173282401
Pompe RS, von Bueren AO, Mynarek M, et al. Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. Eur J Cancer. 2015;51(17):2634-2642. DOI: https://doi.org/10.1016/j.ejca.2015.08.009
Robinson GW, Rudneva VA, Buchhalter I, et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol. 2018;19(6):768-784. DOI: https://doi.org/10.1016/S1470-2045(18)30204-3
Cohen BH, Geyer JR, Miller DC, et al. Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. Pediatr Neurol. 2015;53(1):31-46. DOI: https://doi.org/10.1016/j.pediatrneurol.2015.03.019
Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81(5):690-698. DOI: https://doi.org/10.3171/jns.1994.81.5.0690
Protocolo de tumores del sistema nervioso central en < de 3 años PINDA 2021.
Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer. 2008;50(6):1169-1175. DOI: https://doi.org/10.1002/pbc.21525
Dhall G, O'Neil SH, Ji L, et al. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial. Neuro Oncol. 2020;22(12):1862-1872. DOI: https://doi.org/10.1093/neuonc/noaa102
Edelstein K, Spiegler BJ, Fung S, et al. Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. Neuro Oncol. 2011;13(5):536-545. DOI: https://doi.org/10.1093/neuonc/nor015
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
